Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Cytokinetics: A Heavily Mispriced Cardiovascular Platform
Cytokinetics is positioned as a precision cardiac mechanics platform leader, with aficamten as the first proof-of-concept and multiple pipeline assets. Aficamten's differentiated REMS, rapid titration, and superior safety could disrupt the cardiac myosin inhibitor market, expanding prescriber adoption and accelerating patient switching from competitors. CYTK's robust cash position, efficient commercial model, and underappreciated pipeline support a sum-of-the-parts valuation of $90–$158 per share, far above current levels.
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
Cytokinetics, Incorporated (CYTK) Q3 2025 Earnings Call Transcript
Cytokinetics, Incorporated ( CYTK ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Robert I. Blum - CEO, President & Director Andrew Callos - Executive VP & Chief Commercial Officer Fady Malik - Executive Vice President of Research & Development Stuart Kupfer - Senior VP & Chief Medical Officer Sung Lee - EVP & CFO Conference Call Participants Huidong Wang Salim Syed Zaki Molvi - Jefferies LLC, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Caroline Poacher Maxwell Skor - Morgan Stanley, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Mayank Mamtani - B.
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.59. This compares to a loss of $1.36 per share a year ago.
Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments
Shares of Cytokinetics, which targets medicines for specialty heart diseases, have jumped about 69% over the past three months and are up 31% year to date.
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
Cytokinetics: Specialty Franchise With Aficamten And Ulacamten
CYTK's Aficamten is easily their main value driver. It has an oHCM PDUFA for December 26, 2025. Aficamten's late-cycle FDA meeting is in September. Plus, it has a potential future as a monotherapy, pediatric application, and nHCM Phase 3 expansion. In my view, Aficamten has great safety compared to Camzyos, which failed in its nHCM Phase 3.
Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants & - Corporate Participant Andrew M. Callos - Executive VP & Chief Commercial Officer Diane Weiser - Senior Vice President of Corporate Affairs Fady Ibraham Malik - Executive Vice President of Research Development Robert I.
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to a loss of $1.31 per share a year ago.
Cytokinetics Merits A Speculative Buy Rating
Cytokinetics continues to near unaminous positive analyst sentiment, with most price targets well above current levels, reflecting strong growth expectations. The company's NDA around its lead drug candidate was delayed by three months recently. However, Cytokinetics maintains a robust cash position of $1.1 billion, supporting ongoing operations and R&D. If all goes according to schedule, Cytokinetics should receive the first of many FDA approvals late this year and has several potential catalysts on the horizon.
